Keywords: Pfizer, Wyeth, R&D refocus, Biotherapeutics, Vaccines, Biologics

Prioritized pipeline at “new” Pfizer marks important milestone for the company’s R&D organization

Article | 28 January 2010

Print This

Following its $68 billion acquisition last year of fellow USA-based Wyeth, global drugs behemoth Pfizer yesterday said it will drop testing ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in